IMS-IMWG recommended Consensus Genomic Staging of high-risk MM

The International Myeloma Society (IMS) and the International Myeloma Working Group (IMWG) convened an expert panel of researchers and clinicians to establish an updated, data-driven consensus definition of high-risk multiple myeloma (MM). Avet-Loiseau et al. published a consensus definition based on new evidence from molecular and genomic assays, updated clinical data, and contemporary risk stratification concepts in the Journal of Clinical Oncology.

Key data: High-risk MM should be defined by the presence of at least one of these abnormalities: deletion (del17p) and/or TP53 mutation; translocation (t) including t(4;14), t(14;16), or t(14;20) along with 1q1 and/or del(1p32); monoallelic del(1p32) along with 1q1 or biallelic del(1p32); or β2 microglobulin (≥5.5 mg/L) with normal creatinine (<1.2 mg/dL).

Key learning: The IMS-IMWG Consensus Genomic Staging of high-risk MM is based on data of underlying genomic/molecular features, supporting its ability to improve outcomes in this patient population. The universal use of the definition in clinical trials is recommended to ensure uniformity of high-risk patient populations across future trials.